These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 2544117)

  • 1. Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration.
    Löfdahl CG; Svedmyr N
    Allergy; 1989 May; 44(4):264-71. PubMed ID: 2544117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics.
    Rosenborg J; Bengtsson T; Larsson P; Blomgren A; Persson G; Lötvall J
    Eur J Clin Pharmacol; 2000 Aug; 56(5):363-70. PubMed ID: 11009043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.
    Becker AB; Simons FE
    J Allergy Clin Immunol; 1989 Dec; 84(6 Pt 1):891-5. PubMed ID: 2574732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective and subjective bronchodilation over 12 hours after inhaled formoterol: individual responses.
    Arvidsson P; Larsson S; Löfdahl CG
    J Asthma; 1993; 30(6):459-65. PubMed ID: 8244916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J; Ankerst J
    Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma.
    Sykes AP; Ayres JG
    Respir Med; 1990 Mar; 84(2):135-8. PubMed ID: 2371435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I; Hall IP; McFarlane LC; Lipworth BJ
    J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma.
    Wallin A; Sandström T; Rosenhall L; Melander B
    Thorax; 1993 Jun; 48(6):611-4. PubMed ID: 8346490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours.
    Maesen FP; Smeets JJ; Gubbelmans HL; Zweers PG
    Chest; 1990 Mar; 97(3):590-4. PubMed ID: 1968371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effects of inhaled formoterol and salbutamol on histamine-induced bronchoconstriction--a placebo-controlled study.
    Sovijärvi AR; Reinikainen K; Freudenthal Y; Andersson P; Riska H
    Respiration; 1992; 59(5):279-82. PubMed ID: 1488561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.
    Bjermer L; Rosenborg J; Bengtsson T; Lötvall J
    Ther Adv Respir Dis; 2013 Oct; 7(5):264-71. PubMed ID: 23907810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma.
    Boonsawat W; Charoenratanakul S; Pothirat C; Sawanyawisuth K; Seearamroongruang T; Bengtsson T; Brander R; Selroos O
    Respir Med; 2003 Sep; 97(9):1067-74. PubMed ID: 14509562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
    Bartow RA; Brogden RN
    Drugs; 1998 Feb; 55(2):303-22. PubMed ID: 9506248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment.
    Löfdahl CG; Sigvaldasson A; Skoogh BE; Svedmyr N
    Respiration; 1989; 55 Suppl 2():15-9. PubMed ID: 2572036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients.
    Rosenborg J; Larsson R; Rott Z; Böcskei C; Poczi M; Juhász G
    Respir Med; 2002 Jun; 96(6):412-7. PubMed ID: 12117040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of a single dose of formoterol using an aerosol inhaler in asthmatic children. A randomized, controlled, double-blind study].
    Lebecque P; Vliers S; De Saint-Moulin T; Godding V
    Rev Mal Respir; 1994; 11(1):47-50. PubMed ID: 7907426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.